Cypermethrin

Synonyms: 氯氰菊酯
Cypermethrin 是一种具有口服活性和血脑屏障透过性的 II 类拟除虫菊酯类杀虫剂,可通过延长电压门控钠通道的开放时间,破坏氯离子通道、电压门控钙通道和钾通道的功能,抑制谷氨酸受体、乙酰胆碱受体的活性以及 ATP 酶活性,在神经元细胞中诱发 DNA 损伤与氧化应激,并通过上调 PERK-eIF2α-ATF4-CHOP 轴激活内质网应激,上调 GRP78、caspase-12、caspase-9、caspase-12 和 caspase-3 的表达,诱导细胞凋亡,同时可下调 LHCGR、STAR、CYP11A1、CYP17A1、SOD1 和 SOD2 的表达,上调 DHH 和 AMH 的表达,诱导 ROS 生成,抑制睾丸间质细胞的发育和增殖,诱导自噬,破坏钙稳态和线粒体膜电位,并在动物模型中诱导大鼠黑质纹状体多巴胺能神经退行性变及运动功能障碍,损伤雄性生殖功能,因此可用于帕金森病、雄性生殖毒性、睾丸功能障碍的相关研究。
产品编号: MS-F01699 纯度: 99.93% CAS No.: 52315-07-8 分子式: C22H19Cl2NO3 分子量: 416.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Cypermethrin 是一种具有口服活性和血脑屏障透过性的 II 类拟除虫菊酯类杀虫剂,可通过延长电压门控钠通道的开放时间,破坏氯离子通道、电压门控钙通道和钾通道的功能,抑制谷氨酸受体、乙酰胆碱受体的活性以及 ATP 酶活性,在神经元细胞中诱发 DNA 损伤与氧化应激,并通过上调 PERK-eIF2α-ATF4-CHOP 轴激活内质网应激,上调 GRP78、caspase-12、caspase-9、caspase-12 和 caspase-3 的表达,诱导细胞凋亡,同时可下调 LHCGR、STAR、CYP11A1、CYP17A1、SOD1 和 SOD2 的表达,上调 DHH 和 AMH 的表达,诱导 ROS 生成,抑制睾丸间质细胞的发育和增殖,诱导自噬,破坏钙稳态和线粒体膜电位,并在动物模型中诱导大鼠黑质纹状体多巴胺能神经退行性变及运动功能障碍,损伤雄性生殖功能,因此可用于帕金森病、雄性生殖毒性、睾丸功能障碍的相关研究。

生物实验数据

生物活性 Cypermethrin is an orally active, blood-brain barrier-permeable class II pyrethroid insecticide that prolongs voltage-gated sodium channel opening, disrupts the function of chloride channels, voltage-gated calcium channels, and potassium channels, inhibits glutamate receptor and acetylcholine receptor activity as well as ATPase activity, induces DNA damage and oxidative stress in neuronal cells, activates endoplasmic reticulum stress by upregulating the PERK-eIF2α-ATF4-CHOP axis, upregulates GRP78, caspase-12, caspase-9, caspase-12, and caspase-3 expression, and induces apoptosis, while also downregulating LHCGR, STAR, CYP11A1, CYP17A1, SOD1, and SOD2 expression, upregulating DHH and AMH expression, inducing ROS generation, inhibiting Leydig cell development and proliferation, inducing autophagy, and disrupting calcium homeostasis and mitochondrial membrane potential, and in animal models it induces nigrostriatal dopaminergic neurodegeneration and motor dysfunction in rats and impairs male reproductive function, making it useful for research on Parkinson's disease, male reproductive toxicity, and testicular dysfunction.
体外研究
(In Vitro)

Cypermethrin 可诱导人外周血淋巴细胞发生 DNA 损伤,降低人外周血淋巴细胞的增殖速率指数。
Cypermethrin 通过结合 Phe1519 残基破坏电压门控钠、钾、氯离子通道功能,减慢通道动力学过程,延长通道开放时间,延迟钙调神经磷酸酶磷酸化,阻断 GABA 依赖性氯离子摄取,最终导致神经元过度兴奋。
Cypermethrin (0-80 μM; 24 h) 可诱导 TM3、TM4 小鼠支持细胞发生由内质网应激介导的凋亡,上调 PERK-eIF2α-ATF4-CHOP 以及 caspase-12/caspase-9/caspase-3 的蛋白表达。
Cypermethrin (0-200 μM; 24 h) 显著升高大鼠原代未成熟睾丸间质细胞中的 ROS 水平,降低细胞的线粒体膜电位。
Cypermethrin (1-20 μM; 24 h) 可抑制小鼠睾丸间质细胞 (TM3) 和支持细胞 (TM4) 的增殖。
Cypermethrin (1-20 μM; 24 h) 破坏 TM3 和 TM4 的钙稳态,升高胞质钙水平,线粒体钙水平,破坏细胞线粒体膜维持能力,诱导 线粒体中 Sqstm1/p62 蛋白的累积。
Cypermethrin (20 μM; 4-12 h) 可诱导 TM3 和 TM4 发生时间依赖性自噬激活,升高细胞的 p-Ulk1,p-Sqstm1/p62 表达水平;诱导内质网应激的时间依赖性激活,升高 Ire1α 表达水平。
Cypermethrin (20 μM; 24 h) 可下调 TM3 和 TM4 中多个类固醇生成及精子发生相关基因的表达,包括 Nr2f2、Pr 以及 Ptgs2、Pges、Ptger4。

Apoptosis Analysis

Cell Line: TM4 mouse Sertoli cells
Concentration: 0 μM,10 μM, 20 μM, 40 μM, 80 μM
Incubation Time: 24 h
Result: Increased apoptosis rate of TM4 cells with increasing cypermethrin concentrations.
Showed a statistically significant elevation in the 80 μM group.

Western Blot Analysis

Cell Line: TM4 mouse Sertoli cells
Concentration: 10 μM, 20 μM, 40 μM, 80 μM
Incubation Time: 24 h
Result: Increased GRP78 protein expression, with a statistically significant elevation at 80 μM.
Increased PERK and p-PERK protein expression significantly at 80 μM.
Increased eIF2α protein expression significantly at 40 μM and 80 μM; increased p-eIF2α protein expression significantly at 80 μM.
Increased ATF4 protein expression significantly at 10 μM, 20 μM, 40 μM, and 80 μM.
Increased CHOP protein expression significantly at 40 μM and 80 μM.
Increased Caspase-12 protein expression significantly at 80 μM.
Increased Caspase-9 protein expression significantly at 40 μM and 80 μM.
Increased Caspase-3 protein expression significantly at 80 μM.

Cell Proliferation Assay

Cell Line: mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells
Concentration: 0, 1, 2, 5, 10 and 20 μM
Incubation Time: 24 h
Result: Reduced relative proliferation of TM3 cells by 54% compared to vehicle-treated cells.
Reduced proliferation of TM4 cells by 50% at 5 μM and by 30% at 20 μM compared to vehicle-treated cells.

Apoptosis Analysis

Cell Line: mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells
Concentration: 0, 1, 2, 5, 10 and 20 μM
Incubation Time: 24 h
Result: Increased number of early apoptotic TM3 cells up to two-fold in a dose-dependent manner.
Increased late apoptotic cell death of TM4 cells by approximately 1.5-fold at 20 μM compared to vehicle.

Immunofluorescence

Cell Line: mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Slightly increased Sqstm1/p62 protein levels in the mitochondria of both TM3 and TM4 cells.

Western Blot Analysis

Cell Line: mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells
Concentration: 20 μM
Incubation Time: 4, 8, 12 h
Result: Increased Ulk1 phosphorylation of TM3 cells steadily up to 2.1-fold, and Sqstm1/p62 phosphorylation steadily up to 5.0-fold after 12 h of treatment.
Increased LC3B-II levels of TM3 cells 1.7-fold at 4 h, 1.7-fold at 8 h, and 1.7-fold at 12 h in a time-dependent manner.
Increased p-Ulk1 levels of TM4 cells to 3-fold at 8 h, p-Sqstm1/p62 levels to 4-fold at 8 h, and LC3B-II levels by 3.6-fold after 12 h.\nIncreased Ire1α expression of TM3 cells by 4-fold after 12 h, increased Grp78 expression steadily in a time-dependent manner, increased p-Eif2α time-dependently, and reached highest Gadd153 expression after 8 h.
Increased Ire1α expression of TM4 cells by 6-fold after 12 h, increased Grp78 expression steadily in a time-dependent manner, peaked p-Eif2α at 8 h then decreased, and reached highest Gadd153 expression after 4 h then decreased.

Real Time qPCR

Cell Line: mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Downregulated Nr2f2 mRNA of TM3 cells by 0.38-fold, Ptgs2 mRNA to less than half of vehicle levels, Pges mRNA to less than half of vehicle levels, and Ptger4 mRNA to less than half of vehicle levels.
Downregulated Nr2f2 mRNA of TM4 cells by 0.72-fold, Star mRNA, Ptgs2 mRNA, and Pr mRNA by 0.41-fold.
体内研究
(In Vivo)

Cypermethrin (14.5-145 mg/kg;p.o./i.p.;单次/12 周内 24 次) 会延迟 Wistar 大鼠的发育里程碑并改变其脑区多胺水平,诱导大鼠出现共济失调,诱导大鼠黑质纹状体多巴胺能神经退行性变及运动功能障碍。
Cypermethrin (15 mg/kg;p.o.;妊娠第 5-21 天及出生后第 1-15 天) 可诱导幼年 Charles Wistar 大鼠脑酶活性短暂降低及受体结合改变,且对成年期无持续影响。
Cypermethrin (75 mg/kg;p.o.;每日;连续 15 天) 可诱导 Sprague-Dawley 大鼠出现惊厥行为,加重预先暴露于 6-OHDA (MS-T93142) 的大鼠的黑质纹状体多巴胺能神经元丢失及运动障碍。
Cypermethrin (12.5-50 mg/kg/天;i.g.;每日;14 天) 可抑制青春后期雄性 Sprague-Dawley 大鼠的睾丸间质细胞发育与功能,包括血清睾酮水平降低、促黄体生成素水平升高、睾丸间质细胞数量减少、类固醇生成细胞及支持细胞的基因/蛋白表达失调、氧化应激增强、AKT1 磷酸化水平降低、凋亡相关基因 Bcl2 上调,以及凋亡相关基因 Bax 和蛋白 BAX 下调。

Animal Model: Wistar rats
Dosage: 15 mg/kg;145 mg/kg; 14.5 mg/kg
Administration: p.o.; single dose
Result: Delayed surface righting, eye opening, fur development, incisor eruption, and pinna detachment.
Produced no effect on motor activity.
Altered regional polyamine levels.
Induced ataxia within a few hours, potentiated pentobarbitone-induced sleeping time, enhanced convulsions in pentylenetetrazole co-treated rats at 145 mg/kg dose.
Produced ataxia within a few hours at 14.5 mg/kg dose.
Animal Model: Charles Wistar rats
Dosage: 15 mg/kg
Administration: p.o.; gestation days 5-21 and postnatal days 1-15
Result: Showed no change in dam weight, food/water intake, gestation length, offspring number, or sex ratio.
Produced no effect on monoamine oxidase, sodium-potassium ATPase, or acetylcholinesterase activities, or spiroperidol binding in adulthood.
Decreased sodium-potassium ATPase and acetylcholinesterase activities up to 3 weeks of age.
Increased spiroperidol binding in early life.
Animal Model: Sprague-Dawley rats
Dosage: 15 mg/kg; 75 mg/kg
Administration: p.o.; daily; 15 days
Result: 15 mg/kg dose produced no change in the dopaminergic neuronal system.
75 mg/kg dose induced severe convulsive movement and salivation within a few hours of exposure.
Animal Model: Sprague-Dawley rats (6-OHDA pre-exposed)
Dosage: 15 mg/kg
Administration: p.o.; daily; 15 days
Result: Reduced number of dopaminergic neurons in the substantia nigra.
Reduced number of forepaw adjusting steps.
Animal Model: Sprague-Dawley (male, postnatal day 35 at treatment start, Leydig cell disruption model)
Dosage: 12.5 mg/kg/day; 25 mg/kg/day; 50 mg/kg/day
Administration: i.g.; daily; 14 days
Result: Significantly down-regulated Leydig cell genes Lhcgr, Star, Cyp11a1, and Cyp17a1, Leydig cell protein LHCGR, antioxidant genes Sod1 and Sod2, apoptosis-related gene Bax, and up-regulated Sertoli cell gene Dhh.
Significantly reduced body weight, serum testosterone level, CYP11A1-positive Leydig cell number, testosterone/luteinizing hormone ratio, AKT1 phosphorylation, and CYP11A1 protein density in individual Leydig cells.

性状 固体
颜色 White to off-white

化学信息

分子量 416.30
分子式 C22H19Cl2NO3
CAS No. 52315-07-8
别名 氯氰菊酯

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (240.21 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4021 mL12.0106 mL24.0211 mL60.0528 mL
5 mM0.4804 mL2.4021 mL4.8042 mL12.0106 mL
10 mM0.2402 mL1.2011 mL2.4021 mL6.0053 mL
15 mM0.1601 mL0.8007 mL1.6014 mL4.0035 mL
20 mM0.1201 mL0.6005 mL1.2011 mL3.0026 mL
25 mM0.0961 mL0.4804 mL0.9608 mL2.4021 mL
30 mM0.0801 mL0.4004 mL0.8007 mL2.0018 mL
40 mM0.0601 mL0.3003 mL0.6005 mL1.5013 mL
50 mM0.0480 mL0.2402 mL0.4804 mL1.2011 mL
60 mM0.0400 mL0.2002 mL0.4004 mL1.0009 mL
80 mM0.0300 mL0.1501 mL0.3003 mL0.7507 mL
100 mM0.0240 mL0.1201 mL0.2402 mL0.6005 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

氯氰菊酯 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础